Eli Lilly and Co
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial
Eli Lilly on Thursday said its next-generation obesity drug retatrutide cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. The drug lowered hemoglobin A1c — a key measure of blood sugar levels — by an average of 1.7% to 2% across different doses at […]
Read More
Eli Lilly catches a downgrade as HSBC warns of an overhyped obesity drug market
HSBC analysts just slashed their recommendation on the world’s most valuable pharmaceutical company, Eli Lilly, signaling a potential cooling period for the red-hot obesity drug trade that has come to dominate market narratives of the sector. Analysts led by Rajesh Kumar downgraded Lilly to Reduce from Hold, cutting their target price to $850 from $1,070, […]
Read More
Stocks making the biggest moves premarket: Nvidia, Delta Air Lines, Eli Lilly & more
Check out the companies making the biggest moves premarket: Nvidia — The chipmaker traded slightly higher after CEO Jensen Huang said he expects orders for its Blackwell and Vera Rubin chips to reach $1 trillion through 2027. Delta Air Lines — Shares traded more than 4% higher after the company raised its first-quarter revenue growth […]
Read More
Stocks making the biggest moves premarket: Bumble, Hims & Hers Health, Blue Owl, Netskope & more
Check out the companies making headlines before the bell. Bumble — Bumble shares popped about 21% after the dating app reported strong adjusted EBITDA and revenue results for its fourth quarter. Its first-quarter adjusted EBITDA guidance also beat analyst consensus expectations, per FactSet. Netskope — Shares of the security and networking company plunged 17% on […]
Read More
Hims & Hers shares surge 50% after Novo Nordisk drops patent infringement case over compounded weight loss drugs
Novo Nordisk has dropped its legal case against telehealth provider Hims & Hers over patent infringement, after the two companies agreed Hims would sell Novo’s branded medicines through its platform. “We have decided to drop the current court proceedings and, of course, we reserve to bring that back if need be, but I don’t foresee […]
Read More
Market turmoil is hitting most traditional safe havens. UBS says this is the place to hide
The U.S. and Israel are showing signs of escalating their war against Iran – a move that could batter a variety of assets, even traditional safe havens. To protect their portfolios, investors can snap up stocks from an oft-shorted sector: pharmaceuticals, UBS analysts say. Since the first strikes last Saturday, the Iran War has roiled […]
Read More
Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’
Wegovy is produced by pharmaceutical company Novo Nordisk and has been approved for specifically for chronic weight management in adults and adolescents. (Photo by Steve Christo – Corbis/Corbis via Getty Images) Steve Christo – Corbis | Corbis News | Getty Images The chief executive of drugmaker Zealand Pharma sought to calm investors about the latest […]
Read More
Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.
Eli Lilly on Thursday launched a new program designed to help more employers cover obesity drugs in the U.S., targeting a major barrier to access for patients. Lilly and its chief rival, Novo Nordisk, have moved to slash the cash prices of their popular obesity injections for those who want to pay entirely out-of-pocket. But […]
Read More
Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly
Novo Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its production capacities to make the newly launched Wegovy pill, the Danish drugmaker said Monday. The news comes about two months after Novo launched its blockbuster weight loss drug Wegovy in pill form in the U.S. market, in […]
Read More
Here’s an update on our 4th Industrial Revolution stocks and the rest of the portfolio
On Friday, the CNBC Investing Club held its February Monthly Meeting, where Jim Cramer and Director of Portfolio Analysis ran through each stock in the portfolio. Jim put a special focus on the Club stocks within the artificial intelligence trade. He’s dubbed them the “Fourth Industrial Revolution stocks,” borrowing the term from Nvidia CEO Jensen […]
Read More